InvestorsHub Logo
Followers 276
Posts 32449
Boards Moderated 0
Alias Born 11/14/2013

Re: exwannabe post# 163028

Tuesday, 03/20/2018 5:58:36 PM

Tuesday, March 20, 2018 5:58:36 PM

Post# of 688880
I’m of the mindset statisticians already conducted the final primary endpoint analysis, and NWBO/others placed topline under embargo by/for:
1. Pending publication.
2. Abstract submittal.
3. Keeping NWBO, patients and investigators blinded so that the commercial label includes latest long-tail data. Jmho.
4. Prestige of ASCO (which I don’t agree with.)

I could be wrong. This is simply my opinion.

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News